


# Gateway® TurboGFP-N entry clone

The vector sequence has been compiled using the informa-tion from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced.



For vector sequence, please visit our Web site at

Product	Cat.#	Size
Gateway® TurboGFP-N entry clone	FP522	20 μg
Vector type	Gateway® entry clone	
Reporter	TurboGFP	
Reporter codon usage	mammalian	
Promoter for TurboGFP	NO	
Host cells	prokaryotic	
Selection	kanamycin	
Replication	pUC ori	
Use	Generation of fusions to the N-terminus of TurboGFP; transfer of the construct encoding TurboGFP or its fusion into	

Gateway® destination vectors

#### Multiple cloning site (MCS)



## **Location of features**

attl 1 site: 14-113 MCS: 117-194

Kozak translation initiation site: 195-205

TurboGFP: 202-900 attL2 site: 919-1018

Kanamycin resistance gene: 2236-3030 pUC origin of replication: 3615-4258

#### Vector description

Gateway® TurboGFP-N entry clone is a vector containing green fluorescent protein TurboGFP gene variant with codon usage optimized for high expression in mammalian cells (humanized) [Haas et al. 1996]. TurboGFP coding sequence is flanked by attL1 and attL2 sites allowing easy site-specific recombination. The Invitrogen Gateway® Technology provides a rapid and highly efficient way to transfer the TurboGFP gene into a number of Gateway® destination vectors for expression in different experimental systems. Multiple cloning site (MCS) located at the 5'-end of TurboGFP gene allows to generate fusions to the TurboGFP N-terminus for expression, localization and cellular dynamics studies.

To increase mRNA translation efficiency, Kozak consensus translation initiation site is generated upstream of the TurboGFP coding sequence [Kozak 1987].

The vector backbone contains pUC origin of replication and kanamycin resistance gene (Kan<sup>r</sup>) for propagation and selection in E. coli.

### Generation of TurboGFP fusion proteins

A localization signal or a gene of interest can be cloned into MCS of the vector both before and after sitespecific recombination with a destination vector. It will be expressed as a fusion to the TurboGFP N-terminus when inserted in the same reading frame as TurboGFP and no in-frame stop codons are present.

Alternatively, TurboGFP gene can be fused to the 3'-end of a gene of interest by LR recombination of the Gateway® TurboGFP-N with a destination vector containing this gene in a correct reading frame.

TurboGFP-tagged fusions retain fluorescent properties of the native protein allowing fusion localization in vivo. Note: The plasmid DNA was isolated from dam+-methylated E.coli. Therefore some restriction sites are blocked by methylation. If you wish to digest the vector using such sites you will need to transform the vector into a dam\* host and make fresh DNA.

# LR site-specific recombination

Please refer to Invitrogen Gateway® Technology description for detailed instructions regarding LR site-specific recombination reaction. In general, to transfer TurboGFP gene or TurboGFP-fusion construct into the destination vector you will need:

- Purified plasmid DNA of Gateway® TurboGFP-N
- A destination vector of choice
- Invitrogen LR Clonase TM II enzyme mix (Invitrogen Cat.# 11791-020)
- Proteinase K solution (supplied with the LR Clonase<sup>TM</sup> II enzyme mix)
- TE-Buffer, pH 8.0 (10 mM Tris-HCl, pH 8.0, 1 mM EDTA)
- Appropriate chemically competent E. coli host and growth media for expression
- Appropriate selective plates.

### Propagation in E. coli

Suitable host strains for propagation in E. coli include DH5alpha, HB101, XL1-Blue, and other general purpose strains. Plasmid incompatibility group is pMB1/CoIE1. The vector confers resistance to kanamycin (30  $\mu$ g/ml) to E. coli hosts. Copy number in E. coli is about 500.

### References

Haas, J. et al. (1996) "Codon usage limitation in the expression of HIV-1 envelope glycoprotein." Curr Biol, 6 (3): 315-324 / pmid: 8805248

Kozak, M. (1987) "An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs." Nucleic Acids Res, 15 (20): 8125-8148 / pmid: 3313277

Gateway® Technology. Ver. E. 13 May 2010, 25-0522. http://tools.invitrogen.com/content/sfs/manuals/ gatewayman.pdf (visited on 17.02.2012)

# **Notice to Purchaser:**

TurboGFP-related materials (also referred to as "Products") are intended for research use only.

The Products are covered by U.S. Pat. 7,678,893; European Pat. 1576157; and other Evrogen Patents and/or Patent applications pending. By use of these Products, you accept the terms and conditions of the applicable Limited Use Label License #001: http://www.evrogen.com/products/Evrogen-FP-license.shtml.